Navigation Links
San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research
Date:8/28/2008

HAYWARD, Calif., Aug. 28 /PRNewswire/ -- Guava Technologies, Inc. announced the commencement of an agreement with Hudson Control Group to provide drug discovery researchers with an automated solution for cellular analyses. This non-exclusive agreement is a key component of a larger strategic initiative by Guava Technologies. The initiative is a direct response to a voiced need for sophisticated cell analysis technology to support higher throughput research in a compact, automated, and easy-to-use platform. As part of the agreement, Guava Technologies has established straightforward and worry-free processes for purchase, installation, and service of the complete, integrated solution.

"With this agreement we can immediately deliver an automated walk-away solution for cell analysis to meet the ever-increasing need for higher throughput cell biology that many labs face in today's environment of fast-paced, answer-focused, and efficiency-conscious research," said Lawrence Bruder, CEO, Guava Technologies. "Nothing pleases us more than to meet customer needs, and now, with Hudson, not only can we do that right away, we can also pursue development of even higher value automated solutions going forward."

The new cell analysis system delivers both sample preparation and cell analysis technologies directly to the laboratory benchtop. It is compatible with a range of Guava(R) Turnkey Assays in 96-well format, including the Guava ViaCount(R) Assay for cell counting and viability. The system includes a Guava EasyCyte(TM) Plus Flow Cytometer, a Hudson Control PlateCrane EX robotic arm, and a micro10 liquid dispenser. Once installed and interlinked, it delivers walk-away automated cell analysis effortlessly via integration software from Guava Technologies and Hudson Control Group.

"We have already worked in partnership with Hudson to install this new system in several drug discovery labs," said David King, PhD, VP, R&D and Operations. "So far, response h
'/>"/>

SOURCE Guava Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. 25,000 AIDS Walk San Francisco Participants; 25,000 Reasons Why
2. AIDS Walk San Francisco Takes Big Green Step Forward
3. AIDS Walk San Francisco Boosts Number of Teams and Benefiting Agencies
4. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
5. Thousands to Greet 2,500 Riders as AIDS/LifeCycle Wheels Into L.A. June 7; 7-day, 545-Mile Ride From San Francisco Raises a Record $11.6 Million for HIV/AIDS Services
6. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
7. Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco
8. 2,500 Riders in AIDS/LifeCycle Set to Leave San Francisco June 1, Bound for Los Angeles, Raising a Record $11+ Million for HIV/AIDS Services
9. Staying Sharp in San Francisco: Leading brain experts discuss successful aging
10. Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives
11. Medical Tourism Association Announces Worlds Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Study highlights implications of influenza pandemics on blood supplies 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 3Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 4Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 2Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 4Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 1Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 2Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 4Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 1Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 4Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 1Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 2Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 3
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7